We would love to hear your thoughts about our site and services, please take our survey here.
My point is I just wondered if the comment deliberately vague i.e. the "significant interest in the clinical development of therapeutic cancer vaccines", sounds like a general comment amount the market as a whole, but could it be a subtle clue for something more specific to Scancell's therapeutic cancer vaccines?
Just IMO interesting use of wording.
Interesting last sentence?
"...Following on from AACR, there has been significant interest in the clinical development of therapeutic cancer vaccines, and I am excited to demonstrate the progress Scancell has made in this class of immunotherapies."
Https://find-and-update.company-information.service.gov.uk/company/06564638/filing-history
@JB1 is thus the correction you were expecting?
...but also agree with EE, it is about time Scancell now "show us the money". All this work/research/dedication needs to amount to something.
Excellent post Burble at 08:49, particularly the last paragraph, perfectly explained.
And without academia and academic links, Scancell probably would not exist?
@emptyend - There is annoying impression that this is the case, however you'd think Redmile and Vulpes would not allow this?
Much appreciated RayP.
So do we know if potential suitors to Scancells mAbs portfolio are looking at the infection side of things and not just cancers?
Thanks Ray, forgot to add the link.
To be honest my knowledge of mAbs is limited, didnt realise it could help with bacterial infections too? Anyone care to explain the article in laymans terms?
"Probing the expression and adhesion of glycans involved in Helicobacter pylori infection"
Daniel Sijmons, Simon Collett, Caroline Soliman, Andrew J. Guy, Andrew M. Scott, Lindy G. Durrant, Aaron Elbourne, Anna K. Walduck & Paul A. Ramsland
"...The lectins used for immunofluorescence were Fluorescein Lectin Kit I (FLK-2100) and Fluorescein Lectin Kit II (FLK-3100) supplied by Vector laboratories. The panel of mAbs tested included FG27 and ch88.2 provided by Professor Lindy Durrant (Scancell UK, University of Nottingham UK), "
Interesting?
Excellent post @konara at 10:51.
So Scancell could likely still be in closed period as you say, and yes I wonder how many sold on that RNS?
Btw why have they not RNS'd a correction though?
Https://www.cancertherapyadvisor.com/reports/scib1-vaccine-nivo-ipi-melanoma/
Follow up from AACR.
As also mentioned by marcusl2.
A nice short summary post AACR.
https://www.delveinsight.com/blog/cancer-vaccines-landscape
Thanks C11.
"INAUGURAL AACR ONCOLOGY INDUSTRY PARTNERING EVENT: FROM CANCER DISCOVERIES TO PATIENTS"
https://www.aacr.org/meeting/aacr-oncology-industry-partnering-event/program/
Can't remember if I already posted this, but wonder if Scancell popped by this event also and said hello to a few acquaintances??
RE a comment from sci102:
"...From the abstracts that were released on Friday it doesn't seem that they will present new data. Hopefully that's not the case. sci102"
Logically this sounds correct, but likewise I also hope there is new data. Seems strange to go all that way to one of the most prestegious conferences and not do so?
Can someone explain RE the timing side of things, how info in the abstracts and/or presentation tie in with having disclose anything new via an RNS. Is the fact it's happening on a Sunday the key factor here (assuming there is new info).
@ipad "...Am I right that the patients in the trial were all in stage 4 and still got an 85% ORR. Is there any other treatment that has that effect ? Or even close ?"
I too would love some clarification on this. In particular the point about any other bios being even remotely close to these kind of results?
Inanaco on this topic did say this on the other side:
"...and we are the only company that has a cancer vaccine that has achieved 85% !!"
Thanks Lofas, makes sense. Yes I guess 13 to begin with is small but I was just surprised that a near on 50% increase in patient numbers wasn't mentioned officially...yet.
Should the increase from 13 to 19 patients not have been RNS'd?
Price action*
An interesting day here with the RNS and price acti IMO, again never broke 2.44% gain despite the big buys? Same percentage gain as the last few days I think.
Also IMO interesting news RE Redx:
https://www.proactiveinvestors.co.uk/companies/news/1044346/redx-pharma-plans-to-exit-aim-and-re-register-as-a-private-company-1044346.html